Angion Biomedica Corp.（纳斯达克股票代码：ANGN）认为空头利率将大幅增长

Angion Biomedica Corp. (NASDAQ:ANGN – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 99,700 shares, an increase of 13.4% from the December 15th total of 87,900 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 60,800 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Trading of Angion Biomedica

A number of hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. lifted its position in Angion Biomedica by 102.4% during the 3rd quarter. Prudential Financial Inc. now owns 34,400 shares of the company's stock worth $32,000 after acquiring an additional 17,400 shares during the period. Renaissance Technologies LLC lifted its position in Angion Biomedica by 17.1% during the 1st quarter. Renaissance Technologies LLC now owns 223,700 shares of the company's stock worth $474,000 after acquiring an additional 32,600 shares during the period. CM Management LLC raised its stake in shares of Angion Biomedica by 16.7% during the 2nd quarter. CM Management LLC now owns 525,000 shares of the company's stock worth $599,000 after buying an additional 75,000 shares in the last quarter. Park West Asset Management LLC purchased a new position in shares of Angion Biomedica during the 2nd quarter worth approximately $86,000. Finally, Millennium Management LLC purchased a new position in shares of Angion Biomedica during the 2nd quarter worth approximately $209,000. 17.00% of the stock is owned by institutional investors and hedge funds.

Get Angion Biomedica alerts:

Angion Biomedica Stock Down 4.6 %

Shares of NASDAQ ANGN opened at $0.63 on Friday. The stock has a market cap of $18.97 million, a PE ratio of -1.26 and a beta of 0.59. Angion Biomedica has a 52-week low of $0.59 and a 52-week high of $2.94. The business has a 50-day moving average price of $0.85 and a 200 day moving average price of $0.96.

Angion Biomedica (NASDAQ:ANGN – Get Rating) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.15. Angion Biomedica had a negative return on equity of 22.70% and a negative net margin of 81.45%. Sell-side analysts anticipate that Angion Biomedica will post -1.56 earnings per share for the current year.

About Angion Biomedica

(Get Rating)

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung.

See Also

• Get a free copy of the StockNews.com research report on Angion Biomedica (ANGN)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Angion Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Angion Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.